SEC Form 4 · accession 0001179110-17-015428

BeOne Medicines Ltd. · ONC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — CMO, Hematology

Period of report

Dec 13, 2017

Accepted (ET)

Dec 15, 2017 · 4:05 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001651308

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
American Depositary Shares^F1	Dec 13, 2017	M	1,500	$29.51	A	1,500	D
American Depositary Shares^F1,F2	Dec 13, 2017	S	1,300	$94.2114	D	200	D
American Depositary Shares^F1	Dec 13, 2017	S	200	$94.53	D	0	D
Ordinary Shares	holding	—	—		—	264,900	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Share Option (Right to Buy)^F3,F4	$2.27	Dec 13, 2017	M	19,500	D	—	Sep 2, 2026	Ordinary Shares	1,380,500	1,380,500	D

F1Each American Depositary Share represents 13 Ordinary Shares.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.50 to $94.49, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F3The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.
F4These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events.